Wednesday, July 8, 2026

Patent intelligence · US

US 11219631

Foamable compositions, breakable foams and their uses

granted A61KA61K31/196A61K31/327A61K31/573
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 7
Patent details — US 11219631
Jurisdiction
US
Status
granted
Grant date
Jan 11, 2022
Expiration
Jan 6, 2042
Claims
37
CPC classes
A61K, A61K31/196, A61K31/327, A61K31/573
View on Google Patents ↗

Quick answer

US 11219631 (Foamable compositions, breakable foams and their uses) is held by Vyne Pharmaceuticals Inc.. Status: granted. Granted Jan 11, 2022. Expires Jan 6, 2042 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
37
CPC classes
A61K, A61K31/196, A61K31/327, A61K31/573, A61K31/58, A61K31/7056

More from Vyne Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11433025

    Oil foamable carriers and formulations

    Vyne Therapeutics Inc. · Expires Sep 1, 2042

    granted
  2. US 11103454

    Wax foamable vehicle and pharmaceutical compositions thereof

    Vyne Therapeutics Inc. · Expires Aug 26, 2041

    granted
  3. US 11033491

    Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

    Vyne Therapeutics Inc. · Expires Jun 10, 2041

    granted
  4. US 11026920

    Use of NK-1 receptor antagonist serlopitant in pruritus

    Vyne Therapeutics Inc. · Expires Jun 3, 2041

    granted
  5. US 10967063

    Surfactant-free, water-free formable composition and breakable foams and their uses

    Vyne Therapeutics Inc. · Expires Apr 1, 2041

    granted
  6. US 10946101

    Surfactant-free water-free foamable compositions, breakable foams and gels and their uses

    Vyne Therapeutics Inc. · Expires Mar 11, 2041

    granted

Frequently asked questions

What is US patent 11219631?

US 11219631 (Foamable compositions, breakable foams and their uses) is held by Vyne Pharmaceuticals Inc.. Status: granted. Granted Jan 11, 2022. Expires Jan 6, 2042 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11219631?

Vyne Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.

When does US 11219631 expire?

Our index shows an expiration date of Jan 6, 2042 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.